Definition
Serotonin-norepinephrine reuptake inhibitors, or SNRIs, are a class of medication that increase the availability of both serotonin and norepinephrine in the synapse. Medications in this class include venlafaxine, duloxetine, and desvenlafaxine. They're commonly used for anxiety disorders, depression, and certain chronic pain conditions.
What they can feel like
Effects often resemble those of SSRIs: a quieter baseline, less reactive worry, and improved sleep over time. Some people notice a small lift in energy that SSRIs don't consistently produce, related to the norepinephrine effect. Side effects can include nausea early on, mild blood pressure changes at higher doses, and, with abrupt discontinuation, a distinctive set of withdrawal symptoms that's generally avoidable with a gradual taper.
When they're chosen
An SNRI is often considered when an SSRI hasn't produced an adequate response, when fatigue is a prominent symptom, or when an overlapping chronic pain condition (such as fibromyalgia or chronic low back pain) makes the dual mechanism useful.
Mechanism in brief
SNRIs (serotonin and norepinephrine reuptake inhibitors) block the reuptake transporters for both serotonin and norepinephrine, increasing the availability of both neurotransmitters in the synapse. The serotonin effect tends to predominate at lower doses; the norepinephrine effect becomes more prominent at higher doses, which is part of why SNRIs are often used when fatigue or comorbid pain is part of the picture. As with SSRIs, the clinical effect develops over four to six weeks.
Specific agents and what they're usually chosen for
Three SNRIs see most clinical use. Venlafaxine has the longest track record and a clear dose-response: at lower doses it behaves more like an SSRI, with the norepinephrine effect emerging at higher doses. It's commonly used in generalized anxiety, panic disorder, and depression. Blood pressure can rise modestly at higher doses and is monitored as part of management.
Duloxetine has a more balanced serotonin-norepinephrine effect across its therapeutic range. It's FDA-approved for generalized anxiety disorder, depression, and several chronic pain conditions including diabetic neuropathy and fibromyalgia, which makes it a frequent choice when pain and anxiety co-occur.
Desvenlafaxine is the active metabolite of venlafaxine and reaches a more consistent blood level across patients because it bypasses the variability of the CYP2D6 metabolism that affects venlafaxine. Some patients tolerate it better than venlafaxine for that reason.
Levomilnacipran is occasionally used and has a more prominent norepinephrine effect than the others; clinical experience with it is more limited.
Common side effects and how they're managed
The side effect profile overlaps substantially with SSRIs. Early nausea, headache, and sleep disruption are the most common in the first two weeks and usually resolve. Sexual side effects occur in a meaningful minority and are often the reason patients consider switching. Sweating is more common with SNRIs than with SSRIs because of the norepinephrine effect.
Discontinuation of SNRIs, particularly venlafaxine, requires a slower taper than is typical for SSRIs. Venlafaxine has a short half-life, and abrupt discontinuation can produce uncomfortable withdrawal-like symptoms within 24 to 48 hours. A gradual taper over weeks, with extended-release formulations where possible, is the standard approach.
When an SNRI is preferred over an SSRI
A few clinical situations point toward an SNRI as a reasonable first or second choice. Inadequate response to one or two SSRIs at full dose is the most common reason. Comorbid chronic pain, particularly fibromyalgia, neuropathic pain, or chronic low back pain, favors duloxetine because the dual mechanism addresses both targets. Prominent fatigue or low energy in a depressed patient sometimes favors an SNRI over a more sedating SSRI. The decision and any cross-titration between agents are made with a prescriber; dose adjustment, taper schedule, and monitoring aren't appropriate for patient self-management.
When to see a clinician
If a current SSRI hasn't produced enough response after an adequate trial, if fatigue is prominent, or if a chronic pain condition is part of the picture, an SNRI is a reasonable next conversation with a prescriber. The decision and any cross-titration are made with a clinician.